跳至主要内容
临床试验/CTRI/2021/08/035431
CTRI/2021/08/035431已完成未知

An Open Label, Observational, Prospective, Non-Comparative, Multicentre Real World Study To Evaluate The Clinical Effectiveness And Safety Of Formoterol/Budesonide FDC Delivered Through Synchrobreathe In Patients With Chronic Obstructive Pulmonary Disease - EMERGE

Cipla Ltd0 个研究点目标入组 250 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
Cipla Ltd
入组人数
250

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1)Patient willing to provide signed data sharing consent form. AND
  • 2)Patients of either gender of age 40 years or above with documented diagnosis of COPD as per GOLD 2020 guidelines and CAT score of more than 10 units. AND
  • 3)Patients prescribed formoterol/budesonide FDC through Synchrobreathe inhaler for COPD due to any of the following reason:
  • a) Patient not controlled with current treatment or current ICS/LABA and requires the addition of formoterol/budesonide FDC.
  • b) Unable to use or not satisfied with the previously prescribed inhaler for taking Formoterol/Budesonide FDC.
  • 4)Patients suitable to share data for the study as per Investigator’s discretion

排除标准

  • 1)Hypersensitivity to study drug or any of its components.
  • 2)Acute exacerbation of COPD within past 1 month.
  • 3)Current or previous experience with the use of Synchrobreathe.

研究者

发起方
Cipla Ltd

相似试验

Observational study to determine effectiveness and... | 临床试验